HCV-related fibrosis progression following liver transplantation: increase in recent years.
By M. Berenguer, L. Ferrell, J. Watson, M. Prieto, Michael Kim, M. Rayón, J. Córdoba, A. Herola, N. Ascher, J. Mir and 2 more. Journal of Hepatology, 2000
763 citations recorded by the source corpus.
Subfields: Emergency Medicine, Epidemiology, Hepatology
View Paper: https://www.semanticscholar.org/paper/107b34b0a69f97bf7b8f1a00856ca0d6297f5962
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Epidemiology
- Scott W. Lowe
- Stephen L. Chen
- Lars Zender
- T. Morgan
- Monica Yon
- Stephen A Hearn
- Janelle Simon
- R. Dickins
In Hepatology
- Scott W. Lowe
- Stephen L. Chen
- Lars Zender
- T. Morgan
- Monica Yon
- Stephen A Hearn
- Andrew K. Burroughs
- Janelle Simon
Citations in the corpus
- Senescence of activated stellate cells limits liver fibrosis (2008, background): “Interestingly, as observed in the mouse model studied here, clinical data suggest that immunosuppressed patients more rapidly progress to liver cirrhosis (Berenguer et al., 2000), while immunostimulatory therapy has a protective effect (Rehermann and Nascimbeni, 2005).”
- The Natural History of Hepatitis C Virus (HCV) Infection (2006, background): “Patients with humoral immunoglobulin deficiency (hypogammaglobulinemic) or cellular immune impairment (organ transplant recipients) have shown significantly higher rates of progression to cirrhosis than immunocompetent patients.[42, 45, 46] Insulin resistance appears to be associated with worsening ”
- Computer‐assisted image analysis of liver collagen: Relationship to Ishak scoring and hepatic venous pressure gradient (2009, background): “Numerous studies document rapid histological progression of HCV after liver transplantation, 22 resulting in cirrhosis in up to 30% within 5 years.”